Lantern Pharma Inc.LTRN

Lantern Pharma hosted a webinar on its Open-Medicine multi-agentic AI platform for drug development.

“On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development.”

Lantern Pharma announces presentation on its Open-Medicine AI agentic platform for drug development.

“Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET”

Lantern Pharma describes its subsidiary Open-Medicine AI building a multi-agentic platform for drug development.

“DALLAS — September 23, 2026 — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, will present the growth plan for Open-Medicine AI (OMAI) in a live webinar today at 12:30 PM Eastern. Open Medicine AI is the company’s wholly owned subsidiary building a multi-agentic AI platform for drug development. To register: https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration”

Lantern Pharma states its OMAI platform was built internally and launched commercially as withZeta.ai in 2026.

“CEO Panna Sharma will lead the session and will be joined by the Chief Scientific Officer of Lantern Pharma and the Principal Architect of the multi-agentic platform. OMAI’s core capabilities and initial platform were built inside Lantern’s own clinical programs and areas of focus. The platform launched as withZeta.ai in April 2026, focused on rare cancers, and is now expanding into new diseases, new types of therapies, and additional stages of drug development. Today’s session will show where OMAI is going, share feedback from key user segments, and include a live demonstration of the platform’s most differentiated capabilities.”

Lantern Pharma describes its OMAI multi-agentic platform commercialized as withZeta.ai and expanded with ZetaOmics.

“Open Medicine AI is a wholly owned subsidiary of Lantern Pharma that is building a multi-agentic AI platform for end-to-end therapeutic development. Its AI co-scientists were developed inside Lantern’s clinical-stage oncology programs and carry the data, constraints, and decision points of real drug development — from target and biomarker selection through compound design, translational analysis, trial design, and regulatory strategy. The OMAI platform was first commercialized as withZeta.ai, launched in April 2026 for rare and aggressive cancers, and expanded in July 2026 with ZetaOmics™, a computational biology module released to early-access users. OMAI is extending this architecture to additional disease categories, new therapeutic modalities, and the downstream challenges of drug development. The platform is available to biopharma companies, research institutions, service providers, and drug developers through subscription and enterprise licensing. For more information, visit www.open-medicine.ai.”

Lantern Pharma files 8-K regarding a webinar on its Open-Medicine AI platform.

“On September 23, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release describing topics to be covered during a live webinar hosted by the Company on September 23, 2026 to discuss Open-Medicine AI, a multi-agentic AI platform for drug development. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”

Lantern Pharma established OMAI as a separate company to operate its previously launched multi-agentic AI co-scientist platform.

“Open Medicine AI (OMAI) established as a separate company with board-approved commercial licensing agreements executed, operating the multi-agentic AI co-scientist platform previously launched as withZeta.ai. OMAI is currently wholly owned by Lantern and intends to raise capital at the OMAI level. A dedicated OMAI informational call is planned for mid-September 2026 to detail the market opportunity, platform roadmap, and commercial model.”

Lantern Pharma created OMAI and executed licensing agreements for its multi-agentic AI co-scientist platform.

“In August 2026, Lantern announced the formal creation of Open Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, approved by the Lantern Pharma Board of Directors, were contemplated in the framework of the Company’s May 2026 registered direct financing and establish the commercial operating structure for the multi-agentic AI co-scientist platform previously launched as withZeta.ai. Under the agreements, OMAI licenses Lantern’s related models, data, algorithms, and other assets and personnel.”

Lantern Pharma established an AI Center of Excellence and commercialized its multi-agentic AI platform as OMAI.

“Lantern established an AI Center of Excellence in Bengaluru, India in the first quarter of 2026 and has commercialized its multi-agentic AI capabilities through the platform now operating as Open-Medicine AI (OMAI).”

Lantern Pharma evolves withZeta.ai into the Open-Medicine AI multi-agentic co-scientist platform.

“The Open-Medicine AI multi-agentic co-scientist platform represents the strategic evolution of withZeta.ai and is expanding into additional disease areas and modalities.”

Global AI drug discovery market is projected to exceed $10 billion by 2030.

“The global AI drug discovery and development market is projected to exceed $10 billion by 2030, and Open-Medicine AI enters this market with a differentiated multi-agentic, highly curated platform built for real-world drug development rather than a general-purpose AI.”

Lantern Pharma creates Open-Medicine AI and executes licensing for its multi-agentic co-scientist platform.

“(BUSINESS WIRE) DALLAS – August 3, 2026 — Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lantern Pharma Board approval, are consistent with the framework outlined in Lantern’s most recent registered direct financing and establish the commercial operating structure for the multi-agentic AI co-scientist platform previously launched as withZeta.ai.”

Lantern Pharma forms OMAI to advance multi-agentic AI architecture from oncology into broader diseases.

“OMAI will continue to advance the multi-agentic architecture, first proven in oncology and rare cancer research, while expanding its application across broader disease areas. The formation of the entity and the licensing arrangements position OMAI for independent growth, while expanding value creation opportunities and preserving strategic alignment with Lantern Pharma’s clinical programs and shareholders.”

Lantern CEO describes withZeta.ai multi-agentic co-scientist foundation now scaled via new Open-Medicine AI entity.

““The creation of Open-Medicine AI and the execution of these licensing agreements mark a significant milestone,” said Panna Sharma, President and CEO of Lantern Pharma and Founder of Open-Medicine AI. “withZeta.ai demonstrated that a true multi-agentic co-scientist — specialized agents working in coordinated intelligence rather than a single model answering isolated questions — can dramatically compress research timelines and reduce the cost of generating hardened, actionable scientific insights. Open-Medicine AI takes that proven foundation and gives it the corporate structure, commercial licenses, and operational focus needed to scale across oncology and into additional complex disease areas.””

General-purpose AI firms like Anthropic and OpenAI are entering scientific discovery, requiring domain-specific differentiation.

“At the same time, major general-purpose AI companies — including Anthropic and OpenAI — have publicly signaled or begun developing platforms and tools aimed at scientific discovery and drug development. Their entrance validates the long-term importance of AI co-scientists while also highlighting the differentiation required for durable impact. While general models excel at broad reasoning and language, domain-specific multi-agentic systems grounded in curated ontologies, domain-specific computational tools, and disease-area expertise are required to deliver the precision, auditability, and scientific rigor demanded by drug development.”

Lantern Pharma launched multi-agentic AI platform withZeta.ai commercially.

“Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million”

Lantern Pharma commercially introduced multi-agentic AI platform withZeta.ai.

“Commercial introduction of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development”

Lantern Pharma launched withZeta.ai as external commercial AI product.

“The first quarter of 2026 was defined by capital-efficient execution across Lantern’s clinical and AI platform pipelines. The Company advanced multiple clinical-stage programs through meaningful regulatory and scientific milestones, including a successful outcome from an FDA Type C meeting interaction on the Phase 2 HARMONIC™ trial of LP-300 and IND clearance for the first pediatric CNS cancer program of wholly-owned subsidiary Starlight Therapeutics, while reducing research and development spend by 47% year-over-year. In parallel, Lantern moved its proprietary AI infrastructure from internal capability to external commercial product with the launch of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development. The recent fundraise of up to $9.25 million (which includes the potential future exercise of warrants) further strengthens the Company’s balance sheet and supports continued advancement of both its clinical pipeline and its AI commercialization strategy.”

withZeta.ai is Lantern's first agentic-based commercial AI product.

““withZeta.ai represents Lantern’s first agentic-based commercial AI product, and we believe it is positioned to capture a meaningful share of what we view as a $20 to $50 billion near-term market opportunity in AI-driven drug development,” continued Mr. Sharma . “Separating our withZeta.ai assets into an independent entity is intended to unlock dedicated funding, attract specialized talent, and allow investors to value each business — clinical drug development and AI platforms — on its own terms. Combined with the recent financing, which extends our operating runway into the first quarter of 2027, Lantern enters the remainder of 2026 with a stronger balance sheet, a sharper commercial focus, and a portfolio of AI-driven oncology drug candidates with an estimated combined annual market potential exceeding $15 billion.””

Lantern publicly launched withZeta.ai multi-agentic AI platform in April 2026.

“In April 2026, Lantern publicly launched withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development. The launch was marked by a Nasdaq MarketSite debut, a live demonstration at the American Association for Cancer Research (AACR) 2026 Annual Meeting, and a dedicated investor and analyst webinar covering five oncology use cases ranging from biomarker discovery to clinical trial design optimization. Since its introduction, withZeta.ai has been actively used and evaluated by biotech companies, cancer research centers, biopharma consultants, and institutional investors across the United States, Europe, and Asia.”

withZeta.ai uses multiple specialized AI agents for rare cancer drug development.

“withZeta.ai is designed to accelerate drug development insights, therapeutic strategy generation, cancer trial development, and research workflows across more than 438 rare cancer indications — a category of diseases that collectively represents a massive unmet medical need, but where individual indications have historically been underserved due to small patient populations, sparse and scattered data, and limited commercial incentives. The platform combines multiple specialized AI agents that work collaboratively to analyze genomic data, identify potential therapeutic targets, predict drug-tumor interactions, and generate actionable development strategies, drawing on Lantern’s unique expertise and proprietary data assets in rare and orphan cancer drug development.”

Lantern Pharma plans to spin out its clinically trained AI agent as withZeta.ai.

“The Company has also communicated plans to create an independent business entity composed of the AI platform, withZeta.ai , and related technologies and personnel under the leadership of CEO Mr. Panna Sharma. The Company intends to separate its public facing clinically trained AI agent into an independent business entity in order to access dedicated funding sources and potentially realize valuation multiples separate from its drug development operations, which such entity the Company anticipates will become a newly listed company on a national stock exchange or market. Ryan Lane, from Empery Asset Management, whose funds led the financing round, commented: “We started using the AI platform shortly after its public release and have found the prompt results exceptionally useful for our in-house compound viability analysis versus generic LLM models. We believe with additional funding, withZeta will become a leading AI co-scientist for investors and biotech executives.””

Lantern Pharma demonstrated its multi-agentic AI platform withZeta.ai for cancer drug discovery.

“On April 9, 2026, Lantern Pharma Inc. (the “Company”) utilized a presentation to assist with the Company’s live demonstration of withZeta.ai , the Company’s multi-agentic AI co-scientist for rare cancer drug discovery, development, and clinical trial design. The demonstration included a discussion of the withZeta.ai platform’s capabilities and commercial architecture, the rare cancer market opportunity, competitive positioning, and the Company’s near-term revenue strategy and growth roadmap relating to the platform.”

Presentation on planned April 2026 demonstration of withZeta.ai multi-agentic AI co-scientist platform.

“Presentation relating to April 9, 2026 demonstration of withZeta.ai multi-agentic AI co-scientist platform.”

withZeta.ai multi-agentic co-scientist platform introduced and in beta testing with biotech companies.

“withZeta.ai — Multi-Agentic Co-Scientist Platform: Introduction of withZeta.ai, a first-of-its-kind multi-agentic AI co-scientist platform designed to accelerate drug development insights and therapeutic strategies across more than 438 rare cancers. Since late December 2025, withZeta.ai has been in active demo and beta testing with over 25 biotech companies, cancer research centers, and biopharma consultants, representing a significant near-term commercialization opportunity for the Company’s AI capabilities.”

Company introduced multi-agentic system for rare cancers while advancing clinical programs.

““2025 was a defining year for Lantern Pharma as we achieved clinical validation across multiple programs while establishing the foundation for our next phase of growth,” said Panna Sharma, CEO & President of Lantern Pharma. “The encouraging and developing LP-300 Phase 2 HARMONIC™ observations, combined with successful Phase 1a completion for LP-184 and FDA IND clearance for our pediatric CNS cancer program through Starlight Therapeutics, represent transformational milestones that validate and strengthen our AI-driven approach to precision oncology. Our full-year results reflect disciplined execution with a 19% reduction in total operating expenses year-over-year, even as we advanced multiple clinical programs through key inflection points and introduced a highly unique multi-agentic system aimed at conquering rare cancers. As we move into 2026, we are positioning to advance multiple high-value clinical programs, expand our RADR® platform’s commercial reach and revenue potential globally through our new AI Center of Excellence in India and strengthen our balance sheet.””

withZeta.ai is multi-agentic co-scientist platform for rare cancers.

“withZeta.ai: Multi-Agentic Co-Scientist Platform for Rare Cancers”

Lantern Pharma introduced withZeta.ai multi-agentic AI platform for rare cancer drug development.

“A key commercial milestone in late 2025 was the introduction of withZeta.ai, a first-of-its-kind multi-agentic AI co-scientist platform. withZeta.ai is designed to accelerate drug development insights, therapeutic strategy generation, cancer trial development and research workflows across more than 438 rare cancers — a category of diseases that collectively represents a massive unmet medical need but where individual indications have historically been underserved due to small patient populations, sparse and scattered data and limited commercial incentives.”

withZeta.ai entered demo and beta testing with over 25 biotech and research entities.

“The platform leverages Lantern’s unique expertise and proprietary data assets in rare and orphan cancer drug development, combining multiple specialized AI agents that work collaboratively to analyze genomic data, identify potential therapeutic targets, predict drug-tumor interactions, and generate actionable development strategies. Since late December 2025, withZeta.ai has been in active demo and beta testing with over 25 biotech companies, cancer research centers, and biopharma consultants, generating significant interest and early engagement from the industry.”

Lantern plans to scale withZeta.ai into broader oncology and other therapeutic areas via collaborations.

“Lantern’s longer term plan is to scale withZeta.ai beyond rare cancers into broader oncology indications and, subsequently, into rare diseases and other therapeutic areas through revenue generating collaborations with pharmaceutical companies. The platform’s multi-agentic architecture is designed to be extensible — the same collaborative AI agent framework that powers rare cancer insights can be configured and trained to address drug development challenges across neurology, immunology, metabolic diseases, and other complex therapeutic areas where data fragmentation and scientific complexity represent significant barriers to R&D productivity.”